Holen Sie sich die Stockscreener-App
1.10
8.33%
-0.10
Handel nachbörslich:
1.16
0.06
+5.45%
Schlusskurs vom Vortag:
$1.20
Offen:
$1.21
24-Stunden-Volumen:
985.11K
Relative Volume:
1.18
Marktkapitalisierung:
$61.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.36M
KGV:
-1.6403
EPS:
-0.6706
Netto-Cashflow:
$-23.09M
1W Leistung:
+10.00%
1M Leistung:
+22.15%
6M Leistung:
+35.25%
1J Leistung:
-30.38%
1-Tages-Spanne:
$1.08
$1.22
1-Wochen-Bereich:
$1.01
$1.28
52-Wochen-Spanne:
$0.5068
$1.915
Pds Biotechnology Corp Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corp
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
1.10 | 66.98M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corp Aktie (PDSB) Neueste Nachrichten
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusSpecial Dividend Alert - Newser
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
PDS Biotechnology Q1 2026 earnings preview - MSN
Number of shareholders of PDS Biotechnology Corp. – SWB:EU6 - TradingView
PDS Biotechnology: Juni-Test für Wandelanleihe - kapitalmarktexperten.de
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corp reports results for the quarter ended March 31Earnings Summary - TradingView
PDS Biotechnology (PDSB) posts Q1 2026 loss and plans costly debt redemption - Stock Titan
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript - Sahm
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients - MSN
PDSB Q1 2026 Earnings Transcript - AOL.com
PDS Biotechnology Q1 Earnings Call Highlights - MarketBeat
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
PDS Biotech Reports Q1 2026 Financial Results, Highlights Clinical Progress in Cancer Immunotherapy Trials - Minichart
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
PDSB: Protocol changes accelerate clinical timelines and reduce costs, with improved financials - TradingView
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations - Investing.com
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5% - ChartMill
PDS Biotechnology posts quarterly financial results and updates clinical programs - Traders Union
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings - Quiver Quantitative
PDS Biotechnology reports Q1 2026 net loss $7.3M, cash $21.7M; clinical updates on PDS0101 and PDS01ADC - TradingView
PDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical Update - Quiver Quantitative
PDS Biotechnology: Q1 Earnings Snapshot - marketscreener.com
PDSB: Q1 2026 featured clinical milestones, reduced net loss, and extended patent protection - TradingView
PDS Biotech (Nasdaq: PDSB) trims Q1 loss as R&D spending falls - Stock Titan
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - marketscreener.com
PDS Biotech trial reports 77.8% response in colorectal cancer - Stock Titan
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
TradingKey - TradingKey
PDS Biotechnology Pushes Toward Pivotal Cancer Trial Results With Cash in Focus - AD HOC NEWS
PDS Biotechnology Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
PDS Biotechnology to provide quarterly results and clinical program progress - Traders Union
PDS Biotech to Discuss First Quarter 2026 Financial Results on May 6th - geneonline.com
PDS Biotech to give Q1 results and clinical update May 13 - Stock Titan
- SEC.gov
PDS Biotechnology Refinances Debt with New Note, Warrant - The Globe and Mail
PDS Biotechnology Secures $6 Million Note and New ATM; To Redeem 2025 Debentures - TradingView
PDS Biotech (PDSB) adds $6M note, warrants and new ATM while redeeming debentures - Stock Titan
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April - MarketBeat
PDSB Stock Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corporation announced that it expects to receive $5.76 million in funding - marketscreener.com
[EFFECT] PDS Biotechnology Corp SEC Filing - Stock Titan
PDS Biotech 2025 Executive Compensation, Leadership Structure, and Equity Ownership Overview - Minichart
[10-K/A] PDS Biotechnology Corp Amends Annual Report - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) registers $200M shelf, removes $20M ATM - Stock Titan
PDS Biotechnology: FDA-Alignment für VERSATILE-003 - Börse Global
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts - TradingView
PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC - Stock Titan
Finanzdaten der Pds Biotechnology Corp-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):